The Ministry of Economic Affairs(MOEA) announced that the Development Center for Biotechnology(DCB) has developed a new generation of ADC (antibody-drug conjugate) anti-cancer drugs that can carry two small molecule drugs. The key technology of ADC, “tri-mannosyl conjugation technology,” has been licensed to HoneyBear Biosciences, which is invested by a domestic leading API company SCI Pharmtech, for a license fee of up to 690 million NT dollars.